25 XP   0   0   10

Pharma Mar S.A.
Buy, Hold or Sell?

Let's analyse Pharma Mar S.A. together

PenkeI guess you are interested in Pharma Mar S.A.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharma Mar S.A.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharma Mar S.A.

I send you an email if I find something interesting about Pharma Mar S.A..

Quick analysis of Pharma Mar S.A. (30 sec.)










What can you expect buying and holding a share of Pharma Mar S.A.? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.70
When do you have the money?
1 year
How often do you get paid?
47.5%

What is your share worth?

Current worth
‚ā¨11.00
Expected worth in 1 year
‚ā¨10.03
How sure are you?
55.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨-0.32
Return On Investment
-1.0%

For what price can you sell your share?

Current Price per Share
‚ā¨33.66
Expected price per share
‚ā¨26.16 - ‚ā¨42.30
How sure are you?
50%

1. Valuation of Pharma Mar S.A. (5 min.)




Live pricePrice per Share (EOD)

‚ā¨33.66

Intrinsic Value Per Share

‚ā¨-26.42 - ‚ā¨5.94

Total Value Per Share

‚ā¨-15.41 - ‚ā¨16.95

2. Growth of Pharma Mar S.A. (5 min.)




Is Pharma Mar S.A. growing?

Current yearPrevious yearGrowGrow %
How rich?$206.1m$229.8m-$15.1m-7.1%

How much money is Pharma Mar S.A. making?

Current yearPrevious yearGrowGrow %
Making money$541.8k$7.6m-$7.1m-1,321.1%
Net Profit Margin1.0%16.5%--

How much money comes from the company's main activities?

3. Financial Health of Pharma Mar S.A. (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#258 / 990

Most Revenue
#138 / 990

Most Profit
#139 / 990

Most Efficient
#155 / 990

What can you expect buying and holding a share of Pharma Mar S.A.? (5 min.)

Welcome investor! Pharma Mar S.A.'s management wants to use your money to grow the business. In return you get a share of Pharma Mar S.A..

What can you expect buying and holding a share of Pharma Mar S.A.?

First you should know what it really means to hold a share of Pharma Mar S.A.. And how you can make/lose money.

Speculation

The Price per Share of Pharma Mar S.A. is ‚ā¨33.66. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharma Mar S.A..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharma Mar S.A., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨11.00. Based on the TTM, the Book Value Change Per Share is ‚ā¨-0.24 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.16 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharma Mar S.A..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps0.140.4%0.030.1%0.391.2%0.882.6%0.331.0%
Usd Book Value Change Per Share0.040.1%-0.26-0.8%0.210.6%0.571.7%0.200.6%
Usd Dividend Per Share0.000.0%0.170.5%0.170.5%0.160.5%0.140.4%
Usd Total Gains Per Share0.040.1%-0.09-0.3%0.381.1%0.722.1%0.341.0%
Usd Price Per Share30.74-35.41-61.56-50.04-26.42-
Price to Earnings Ratio54.69-37.57-63.64-28.69-11.50-
Price-to-Total Gains Ratio735.65-149.05-88.31-60.93-29.80-
Price to Book Ratio2.61-2.94-4.84-5.39-3.30-
Price-to-Total Gains Ratio735.65-149.05-88.31-60.93-29.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share36.006102
Number of shares27
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.170.16
Usd Book Value Change Per Share-0.260.57
Usd Total Gains Per Share-0.090.72
Gains per Quarter (27 shares)-2.3519.51
Gains per Year (27 shares)-9.3878.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
119-28-19176168
238-56-2834122146
356-84-3750184224
475-113-4667245302
594-141-5584306380
6113-169-64101367458
7131-197-73118429536
8150-225-82135490614
9169-253-91151551692
10188-282-100168612770

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%22.018.00.055.0%26.035.00.042.6%
Book Value Change Per Share1.03.00.025.0%8.04.00.066.7%13.07.00.065.0%19.021.00.047.5%25.036.00.041.0%
Dividend per Share1.00.03.025.0%3.00.09.025.0%8.00.012.040.0%19.00.021.047.5%21.00.040.034.4%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%14.06.00.070.0%22.018.00.055.0%29.032.00.047.5%

Fundamentals of Pharma Mar S.A.

About Pharma Mar S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Fundamental data was last updated by Penke on 2024-06-11 14:53:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Pharma Mar S.A..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Pharma Mar S.A. earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Pharma Mar S.A. to the¬†Biotechnology industry mean.
  • A Net Profit Margin of 6.1%¬†means that¬†€0.06 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharma Mar S.A.:

  • The MRQ is 6.1%. The company is making a profit. +1
  • The TTM is 1.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.1%TTM1.0%+5.0%
TTM1.0%YOY16.5%-15.5%
TTM1.0%5Y21.9%-20.9%
5Y21.9%10Y6.3%+15.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1%-168.6%+174.7%
TTM1.0%-223.2%+224.2%
YOY16.5%-242.8%+259.3%
5Y21.9%-392.9%+414.8%
10Y6.3%-503.2%+509.5%
1.1.2. Return on Assets

Shows how efficient Pharma Mar S.A. is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Pharma Mar S.A. to the¬†Biotechnology industry mean.
  • 0.7% Return on Assets means that¬†Pharma Mar S.A. generated¬†€0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharma Mar S.A.:

  • The MRQ is 0.7%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.1%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.7%TTM0.1%+0.6%
TTM0.1%YOY1.9%-1.7%
TTM0.1%5Y4.2%-4.1%
5Y4.2%10Y1.3%+2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7%-11.6%+12.3%
TTM0.1%-11.5%+11.6%
YOY1.9%-10.9%+12.8%
5Y4.2%-12.9%+17.1%
10Y1.3%-14.2%+15.5%
1.1.3. Return on Equity

Shows how efficient Pharma Mar S.A. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Pharma Mar S.A. to the¬†Biotechnology industry mean.
  • 1.2% Return on Equity means Pharma Mar S.A. generated €0.01¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharma Mar S.A.:

  • The MRQ is 1.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.2%TTM0.2%+1.0%
TTM0.2%YOY3.4%-3.2%
TTM0.2%5Y-401.3%+401.5%
5Y-401.3%10Y-206.7%-194.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2%-13.8%+15.0%
TTM0.2%-14.6%+14.8%
YOY3.4%-13.6%+17.0%
5Y-401.3%-18.1%-383.2%
10Y-206.7%-19.0%-187.7%

1.2. Operating Efficiency of Pharma Mar S.A..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharma Mar S.A. is operating .

  • Measures how much profit Pharma Mar S.A. makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Pharma Mar S.A. to the¬†Biotechnology industry mean.
  • An Operating Margin of -11.5%¬†means the company generated €-0.11 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharma Mar S.A.:

  • The MRQ is -11.5%. The company is operating very inefficient. -2
  • The TTM is -4.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-11.5%TTM-4.4%-7.1%
TTM-4.4%YOY12.4%-16.8%
TTM-4.4%5Y19.4%-23.8%
5Y19.4%10Y5.8%+13.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.5%-340.8%+329.3%
TTM-4.4%-230.7%+226.3%
YOY12.4%-258.7%+271.1%
5Y19.4%-384.5%+403.9%
10Y5.8%-489.8%+495.6%
1.2.2. Operating Ratio

Measures how efficient Pharma Mar S.A. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of 1.11 means that the operating costs are €1.11 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Pharma Mar S.A.:

  • The MRQ is 1.114. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.042. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.114TTM1.042+0.072
TTM1.042YOY0.877+0.165
TTM1.0425Y0.801+0.240
5Y0.80110Y0.939-0.138
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1143.052-1.938
TTM1.0423.291-2.249
YOY0.8773.562-2.685
5Y0.8014.839-4.038
10Y0.9396.206-5.267

1.3. Liquidity of Pharma Mar S.A..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharma Mar S.A. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 2.62¬†means the company has €2.62 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharma Mar S.A.:

  • The MRQ is 2.616. The company is able to pay all its short-term debts. +1
  • The TTM is 2.849. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.616TTM2.849-0.233
TTM2.849YOY2.884-0.035
TTM2.8495Y2.594+0.255
5Y2.59410Y1.931+0.662
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6163.767-1.151
TTM2.8494.032-1.183
YOY2.8844.958-2.074
5Y2.5945.974-3.380
10Y1.9316.338-4.407
1.3.2. Quick Ratio

Measures if Pharma Mar S.A. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Pharma Mar S.A. to the¬†Biotechnology industry mean.
  • A Quick Ratio of 3.37¬†means the company can pay off €3.37 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharma Mar S.A.:

  • The MRQ is 3.367. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.485. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.367TTM3.485-0.118
TTM3.485YOY2.919+0.567
TTM3.4855Y2.964+0.521
5Y2.96410Y2.046+0.918
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3673.141+0.226
TTM3.4853.604-0.119
YOY2.9194.808-1.889
5Y2.9645.825-2.861
10Y2.0466.378-4.332

1.4. Solvency of Pharma Mar S.A..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharma Mar S.A. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Pharma Mar S.A. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.42¬†means that Pharma Mar S.A. assets are¬†financed with 42.3% credit (debt) and the remaining percentage (100% - 42.3%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Pharma Mar S.A.:

  • The MRQ is 0.423. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.420. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.423TTM0.420+0.003
TTM0.420YOY0.441-0.021
TTM0.4205Y0.606-0.186
5Y0.60610Y0.690-0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4230.336+0.087
TTM0.4200.347+0.073
YOY0.4410.289+0.152
5Y0.6060.369+0.237
10Y0.6900.381+0.309
1.4.2. Debt to Equity Ratio

Measures if Pharma Mar S.A. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Pharma Mar S.A. to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 73.3% means that company has €0.73 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharma Mar S.A.:

  • The MRQ is 0.733. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.724. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.733TTM0.724+0.009
TTM0.724YOY0.790-0.065
TTM0.7245Y53.367-52.642
5Y53.36710Y28.675+24.692
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7330.372+0.361
TTM0.7240.419+0.305
YOY0.7900.372+0.418
5Y53.3670.446+52.921
10Y28.6750.476+28.199

2. Market Valuation of Pharma Mar S.A.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Pharma Mar S.A. generates.

  • Above 15 is considered overpriced but¬†always compare¬†Pharma Mar S.A. to the¬†Biotechnology industry mean.
  • A PE ratio of 54.69 means the investor is paying €54.69¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharma Mar S.A.:

  • The EOD is 64.056. Based on the earnings, the company is expensive. -2
  • The MRQ is 54.693. Based on the earnings, the company is expensive. -2
  • The TTM is 37.570. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD64.056MRQ54.693+9.363
MRQ54.693TTM37.570+17.123
TTM37.570YOY63.639-26.069
TTM37.5705Y28.689+8.881
5Y28.68910Y11.496+17.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD64.056-2.241+66.297
MRQ54.693-2.903+57.596
TTM37.570-2.857+40.427
YOY63.639-3.454+67.093
5Y28.689-6.141+34.830
10Y11.496-6.401+17.897
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharma Mar S.A.:

  • The EOD is 73.080. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 62.398. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 5.040. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD73.080MRQ62.398+10.682
MRQ62.398TTM5.040+57.357
TTM5.040YOY-42.276+47.316
TTM5.0405Y-77.581+82.621
5Y-77.58110Y-40.385-37.195
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD73.080-2.850+75.930
MRQ62.398-3.599+65.997
TTM5.040-3.642+8.682
YOY-42.276-4.800-37.476
5Y-77.581-7.853-69.728
10Y-40.385-8.420-31.965
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharma Mar S.A. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of 2.61 means the investor is paying €2.61¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharma Mar S.A.:

  • The EOD is 3.059. Based on the equity, the company is fair priced.
  • The MRQ is 2.612. Based on the equity, the company is underpriced. +1
  • The TTM is 2.940. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.059MRQ2.612+0.447
MRQ2.612TTM2.940-0.329
TTM2.940YOY4.837-1.897
TTM2.9405Y5.392-2.452
5Y5.39210Y3.299+2.093
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.0591.852+1.207
MRQ2.6122.209+0.403
TTM2.9402.225+0.715
YOY4.8372.441+2.396
5Y5.3923.709+1.683
10Y3.2994.178-0.879
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharma Mar S.A. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.039-0.244+724%0.194-80%0.530-93%0.185-79%
Book Value Per Share--11.00511.285-2%11.912-8%7.849+40%5.225+111%
Current Ratio--2.6162.849-8%2.884-9%2.594+1%1.931+35%
Debt To Asset Ratio--0.4230.420+1%0.441-4%0.606-30%0.690-39%
Debt To Equity Ratio--0.7330.724+1%0.790-7%53.367-99%28.675-97%
Dividend Per Share---0.163-100%0.163-100%0.146-100%0.134-100%
Eps--0.1310.027+383%0.365-64%0.826-84%0.309-58%
Free Cash Flow Per Share--0.115-0.485+521%0.021+447%0.765-85%0.317-64%
Free Cash Flow To Equity Per Share---0.269-0.929+245%-0.254-6%0.306-188%0.097-377%
Gross Profit Margin---1.411-0.496-65%-1.678+19%0.161-978%3.019-147%
Intrinsic Value_10Y_max--5.941--------
Intrinsic Value_10Y_min---26.416--------
Intrinsic Value_1Y_max--1.173--------
Intrinsic Value_1Y_min---0.345--------
Intrinsic Value_3Y_max--3.085--------
Intrinsic Value_3Y_min---3.036--------
Intrinsic Value_5Y_max--4.465--------
Intrinsic Value_5Y_min---7.898--------
Market Cap588662910.000+15%503175982.620588204550.560-14%1037489779.135-52%843382005.345-40%445728632.031+13%
Net Profit Margin--0.0610.010+483%0.165-63%0.219-72%0.063-3%
Operating Margin---0.115-0.044-62%0.124-193%0.194-159%0.058-297%
Operating Ratio--1.1141.042+7%0.877+27%0.801+39%0.939+19%
Pb Ratio3.059+15%2.6122.940-11%4.837-46%5.392-52%3.299-21%
Pe Ratio64.056+15%54.69337.570+46%63.639-14%28.689+91%11.496+376%
Price Per Share33.660+15%28.74033.100-13%57.545-50%46.776-39%24.695+16%
Price To Free Cash Flow Ratio73.080+15%62.3985.040+1138%-42.276+168%-77.581+224%-40.385+165%
Price To Total Gains Ratio861.590+15%735.653149.051+394%88.308+733%60.926+1107%29.804+2368%
Quick Ratio--3.3673.485-3%2.919+15%2.964+14%2.046+65%
Return On Assets--0.0070.001+423%0.019-63%0.042-84%0.013-46%
Return On Equity--0.0120.002+500%0.034-65%-4.013+33717%-2.067+17415%
Total Gains Per Share--0.039-0.081+308%0.357-89%0.676-94%0.319-88%
Usd Book Value--206103377.800214637711.825-4%229805790.400-10%151012704.615+36%101092453.123+104%
Usd Book Value Change Per Share--0.042-0.261+724%0.207-80%0.567-93%0.198-79%
Usd Book Value Per Share--11.77212.071-2%12.742-8%8.397+40%5.590+111%
Usd Dividend Per Share---0.174-100%0.175-100%0.156-100%0.143-100%
Usd Eps--0.1410.029+383%0.391-64%0.884-84%0.331-58%
Usd Free Cash Flow--2156515.200-9301041.500+531%416113.300+418%15009388.580-86%6221936.793-65%
Usd Free Cash Flow Per Share--0.123-0.519+521%0.023+447%0.818-85%0.339-64%
Usd Free Cash Flow To Equity Per Share---0.288-0.994+245%-0.272-6%0.327-188%0.104-377%
Usd Market Cap629692714.827+15%538247348.609629202407.734-14%1109802816.741-52%902165731.118-40%476795917.684+13%
Usd Price Per Share36.006+15%30.74335.407-13%61.556-50%50.036-39%26.416+16%
Usd Profit--2460310.000541803.050+354%7699700.600-68%15083625.760-84%5829276.665-58%
Usd Revenue--40612230.20043360289.500-6%47370594.800-14%51272539.490-21%48345225.213-16%
Usd Total Gains Per Share--0.042-0.087+308%0.382-89%0.723-94%0.341-88%
 EOD+4 -4MRQTTM+18 -18YOY+11 -255Y+11 -2510Y+13 -23

3.2. Fundamental Score

Let's check the fundamental score of Pharma Mar S.A. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1564.056
Price to Book Ratio (EOD)Between0-13.059
Net Profit Margin (MRQ)Greater than00.061
Operating Margin (MRQ)Greater than0-0.115
Quick Ratio (MRQ)Greater than13.367
Current Ratio (MRQ)Greater than12.616
Debt to Asset Ratio (MRQ)Less than10.423
Debt to Equity Ratio (MRQ)Less than10.733
Return on Equity (MRQ)Greater than0.150.012
Return on Assets (MRQ)Greater than0.050.007
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Pharma Mar S.A. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.612
Ma 20Greater thanMa 5036.370
Ma 50Greater thanMa 10033.379
Ma 100Greater thanMa 20032.445
OpenGreater thanClose34.620
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-03-312023-06-302023-09-302023-12-312024-03-31
Net Debt  -76,32343,931-32,3925,995-26,3979,741-16,65621,2074,551



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets333,898
Total Liabilities141,224
Total Stockholder Equity192,674
 As reported
Total Liabilities 141,224
Total Stockholder Equity+ 192,674
Total Assets = 333,898

Assets

Total Assets333,898
Total Current Assets241,357
Long-term Assets92,541
Total Current Assets
Cash And Cash Equivalents 35,709
Short-term Investments 124,010
Net Receivables 26,945
Inventory 43,478
Other Current Assets 11,215
Total Current Assets  (as reported)241,357
Total Current Assets  (calculated)241,357
+/-0
Long-term Assets
Property Plant Equipment 53,740
Long-term Assets  (as reported)92,541
Long-term Assets  (calculated)53,740
+/- 38,801

Liabilities & Shareholders' Equity

Total Current Liabilities92,270
Long-term Liabilities48,954
Total Stockholder Equity192,674
Total Current Liabilities
Short-term Debt 12,794
Short Long Term Debt 10,920
Accounts payable 34,631
Other Current Liabilities 19,571
Total Current Liabilities  (as reported)92,270
Total Current Liabilities  (calculated)77,916
+/- 14,354
Long-term Liabilities
Long term Debt 25,886
Capital Lease Obligations 3,454
Long-term Liabilities Other 194
Long-term Liabilities  (as reported)48,954
Long-term Liabilities  (calculated)29,534
+/- 19,420
Total Stockholder Equity
Common Stock11,013
Retained Earnings 144,091
Other Stockholders Equity 37,570
Total Stockholder Equity (as reported)192,674
Total Stockholder Equity (calculated)192,674
+/-0
Other
Capital Stock11,013
Cash and Short Term Investments 159,719
Common Stock Shares Outstanding 17,508
Current Deferred Revenue25,274
Liabilities and Stockholders Equity 333,898
Net Debt 4,551
Net Invested Capital 229,480
Net Working Capital 149,087
Property Plant and Equipment Gross 53,740
Short Long Term Debt Total 40,260



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-31
> Total Assets 
0
0
0
207,540
206,152
231,050
228,539
211,314
215,986
242,725
238,550
230,823
220,888
227,721
221,028
217,816
212,203
230,490
218,473
199,830
216,484
207,367
201,867
189,370
205,202
220,042
213,559
201,389
205,770
223,109
245,691
211,939
217,991
220,531
209,525
221,137
216,641
222,195
202,710
187,720
185,649
190,618
174,850
157,676
166,103
129,738
112,537
124,705
275,611
352,227
329,731
330,259
345,102
342,542
347,692
368,386
378,028
390,772
379,098
393,259
373,717
358,690
349,412
341,223
333,898
333,898341,223349,412358,690373,717393,259379,098390,772378,028368,386347,692342,542345,102330,259329,731352,227275,611124,705112,537129,738166,103157,676174,850190,618185,649187,720202,710222,195216,641221,137209,525220,531217,991211,939245,691223,109205,770201,389213,559220,042205,202189,370201,867207,367216,484199,830218,473230,490212,203217,816221,028227,721220,888230,823238,550242,725215,986211,314228,539231,050206,152207,540000
   > Total Current Assets 
0
0
0
124,925
124,934
149,540
147,732
126,386
131,402
157,917
153,753
143,407
133,428
139,527
133,636
129,531
124,195
142,453
130,792
106,431
122,688
113,966
107,960
95,895
111,435
122,430
116,761
101,916
104,992
120,742
140,333
112,135
118,599
122,056
109,847
120,992
113,904
123,647
104,299
93,176
92,188
97,930
88,272
75,110
39,881
66,874
50,751
49,976
202,583
259,470
237,859
245,651
261,420
276,683
280,941
295,231
289,149
274,689
265,939
275,183
257,475
267,839
260,973
252,602
241,357
241,357252,602260,973267,839257,475275,183265,939274,689289,149295,231280,941276,683261,420245,651237,859259,470202,58349,97650,75166,87439,88175,11088,27297,93092,18893,176104,299123,647113,904120,992109,847122,056118,599112,135140,333120,742104,992101,916116,761122,430111,43595,895107,960113,966122,688106,431130,792142,453124,195129,531133,636139,527133,428143,407153,753157,917131,402126,386147,732149,540124,934124,925000
       Cash And Cash Equivalents 
0
0
0
37,807
29,196
33,686
45,977
37,246
34,017
20,470
22,896
40,595
29,007
24,831
18,825
30,381
19,653
25,125
26,424
18,336
30,432
13,630
14,572
22,458
19,626
22,723
23,898
16,551
14,951
22,943
39,533
7,629
6,550
8,633
10,595
14,290
11,926
19,628
13,670
24,088
15,886
14,677
26,164
22,745
10,385
39,327
23,409
17,638
153,992
208,892
93,222
96,210
106,432
129,587
132,167
113,348
152,255
142,723
129,433
149,813
119,711
76,070
69,975
60,024
35,709
35,70960,02469,97576,070119,711149,813129,433142,723152,255113,348132,167129,587106,43296,21093,222208,892153,99217,63823,40939,32710,38522,74526,16414,67715,88624,08813,67019,62811,92614,29010,5958,6336,5507,62939,53322,94314,95116,55123,89822,72319,62622,45814,57213,63030,43218,33626,42425,12519,65330,38118,82524,83129,00740,59522,89620,47034,01737,24645,97733,68629,19637,807000
       Short-term Investments 
0
0
0
0
24,565
28,692
26,254
0
26,133
43,205
38,991
25,985
20,437
16,633
23,512
18,944
17,402
24,614
18,074
16,092
8,141
6,062
6,470
6,377
13,648
12,707
12,518
18,960
15,778
7,840
9,641
37,996
36,965
30,803
21,797
18,077
28,188
21,471
17,872
7,671
7,674
4,270
4,265
4,131
3,393
3,394
3,597
3,257
19,612
19,214
104,023
99,306
103,627
87,145
88,947
88,532
69,333
53,973
56,917
32,607
63,416
108,826
104,378
102,538
124,010
124,010102,538104,378108,82663,41632,60756,91753,97369,33388,53288,94787,145103,62799,306104,02319,21419,6123,2573,5973,3943,3934,1314,2654,2707,6747,67117,87221,47128,18818,07721,79730,80336,96537,9969,6417,84015,77818,96012,51812,70713,6486,3776,4706,0628,14116,09218,07424,61417,40218,94423,51216,63320,43725,98538,99143,20526,133026,25428,69224,5650000
       Net Receivables 
0
0
0
55,851
39,325
0
46,503
61,207
41,644
64,742
64,587
42,829
50,350
65,580
60,581
52,151
55,662
61,865
59,080
48,952
53,584
65,445
62,193
44,832
49,945
58,592
54,669
0
42,657
60,635
62,683
0
47,588
55,832
51,544
62,569
43,894
51,717
44,259
31,319
36,510
48,249
32,844
23,549
72,739
11,678
11,682
14,577
16,793
18,282
27,452
27,707
26,850
27,997
26,036
60,255
30,801
32,497
30,536
41,908
24,447
26,488
30,182
47,834
26,945
26,94547,83430,18226,48824,44741,90830,53632,49730,80160,25526,03627,99726,85027,70727,45218,28216,79314,57711,68211,67872,73923,54932,84448,24936,51031,31944,25951,71743,89462,56951,54455,83247,588062,68360,63542,657054,66958,59249,94544,83262,19365,44553,58448,95259,08061,86555,66252,15160,58165,58050,35042,82964,58764,74241,64461,20746,503039,32555,851000
       Other Current Assets 
0
0
0
4,827
2,770
29,442
2,914
3,894
2,631
2,295
2,661
4,801
3,309
2,411
3,044
2,746
2,730
3,646
1,906
-451
3,142
1,717
1,171
-4
2,420
3,306
1,473
42,001
2,969
2,145
2,180
43,520
2,540
2,007
2,912
66,467
4,624
6,169
5,354
37,513
5,271
4,833
5,126
27,618
-56,603
3,386
3,522
5,602
3,461
3,506
4,588
10,495
15,789
21,210
23,252
22,560
21,027
26,906
27,546
23,109
17,283
20,896
21,546
2,917
11,215
11,2152,91721,54620,89617,28323,10927,54626,90621,02722,56023,25221,21015,78910,4954,5883,5063,4615,6023,5223,386-56,60327,6185,1264,8335,27137,5135,3546,1694,62466,4672,9122,0072,54043,5202,1802,1452,96942,0011,4733,3062,420-41,1711,7173,142-4511,9063,6462,7302,7463,0442,4113,3094,8012,6612,2952,6313,8942,91429,4422,7704,827000
   > Long-term Assets 
0
0
0
82,615
81,218
81,510
80,807
84,928
84,584
84,808
84,797
87,416
87,460
88,194
87,392
88,285
88,008
88,037
87,681
92,948
93,345
93,045
93,844
93,471
93,767
97,612
96,798
99,473
100,778
102,367
105,358
99,804
99,392
98,475
99,678
100,145
102,737
98,548
98,411
94,544
93,461
92,688
86,578
82,566
65,987
62,864
61,786
74,729
73,028
92,757
91,872
84,608
83,681
65,859
66,751
73,155
88,879
116,083
113,159
118,076
116,242
90,851
88,439
88,621
92,541
92,54188,62188,43990,851116,242118,076113,159116,08388,87973,15566,75165,85983,68184,60891,87292,75773,02874,72961,78662,86465,98782,56686,57892,68893,46194,54498,41198,548102,737100,14599,67898,47599,39299,804105,358102,367100,77899,47396,79897,61293,76793,47193,84493,04593,34592,94887,68188,03788,00888,28587,39288,19487,46087,41684,79784,80884,58484,92880,80781,51081,21882,615000
       Property Plant Equipment 
0
0
0
39,903
39,773
39,343
38,743
39,062
38,243
37,786
37,373
36,570
35,753
35,307
34,498
33,862
32,825
32,348
31,490
29,794
29,290
29,040
28,800
27,959
27,857
28,288
28,686
29,218
30,367
30,678
31,116
30,624
30,946
30,954
31,473
31,141
30,929
30,863
30,978
31,207
31,111
31,333
27,059
26,637
25,899
26,620
26,473
25,797
24,985
25,118
24,990
25,499
26,753
27,180
28,745
30,605
30,639
30,077
27,688
34,715
34,148
39,186
43,006
47,607
53,740
53,74047,60743,00639,18634,14834,71527,68830,07730,63930,60528,74527,18026,75325,49924,99025,11824,98525,79726,47326,62025,89926,63727,05931,33331,11131,20730,97830,86330,92931,14131,47330,95430,94630,62431,11630,67830,36729,21828,68628,28827,85727,95928,80029,04029,29029,79431,49032,34832,82533,86234,49835,30735,75336,57037,37337,78638,24339,06238,74339,34339,77339,903000
       Goodwill 
0
0
0
2,548
0
0
0
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
2,548
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000002,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5482,5480002,548000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,138
1,022
1,021
1,024
977
947
963
885
884
872
868
822
1,029
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,0298228688728848859639479771,0241,0211,0221,13800000000000000000000000000000000000
       Intangible Assets 
0
0
0
11,769
0
0
0
12,528
12,763
13,232
13,775
14,448
14,955
15,920
16,736
17,325
18,063
18,186
18,552
19,744
20,437
20,840
21,412
22,590
23,019
23,535
24,735
26,288
26,420
27,584
26,128
26,829
26,106
25,382
25,756
24,900
24,148
23,659
23,143
20,212
19,301
18,382
17,443
16,658
5,691
4,763
3,949
6,074
5,287
4,785
0
3,860
0
0
0
3,233
0
0
0
2,589
2,403
2,220
0
1,935
0
01,93502,2202,4032,5890003,2330003,86004,7855,2876,0743,9494,7635,69116,65817,44318,38219,30120,21223,14323,65924,14824,90025,75625,38226,10626,82926,12827,58426,42026,28824,73523,53523,01922,59021,41220,84020,43719,74418,55218,18618,06317,32516,73615,92014,95514,44813,77513,23212,76312,52800011,769000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
451
451
356
63
4
0
0
0
0
0
0
0
0
0
0
0
56,188
44,090
43,004
40,718
51,192
39,554
39,462
38,643
42,555
60,235
30,613
30,542
47,243
41,727
41,802
41,791
37,890
1
34,261
33,736
34,409
27,443
28,298
28,103
30,529
30,807
31,164
0
0
0
00031,16430,80730,52928,10328,29827,44334,40933,73634,261137,89041,79141,80241,72747,24330,54230,61360,23542,55538,64339,46239,55451,19240,71843,00444,09056,188000000000004633564514510000000000000000000
> Total Liabilities 
0
0
0
158,196
160,737
182,055
182,087
170,178
175,507
203,631
201,625
195,963
189,824
198,272
198,244
183,314
183,339
185,503
177,532
161,104
161,945
154,489
149,213
139,935
139,350
154,948
147,781
141,320
139,641
150,581
168,779
138,903
152,521
161,887
153,414
172,642
170,545
179,003
167,480
164,736
164,003
164,484
146,610
140,203
158,606
133,518
121,746
117,249
198,229
248,729
231,581
227,537
217,577
207,688
204,487
190,468
176,227
183,836
166,594
170,302
156,786
148,388
143,217
147,785
141,224
141,224147,785143,217148,388156,786170,302166,594183,836176,227190,468204,487207,688217,577227,537231,581248,729198,229117,249121,746133,518158,606140,203146,610164,484164,003164,736167,480179,003170,545172,642153,414161,887152,521138,903168,779150,581139,641141,320147,781154,948139,350139,935149,213154,489161,945161,104177,532185,503183,339183,314198,244198,272189,824195,963201,625203,631175,507170,178182,087182,055160,737158,196000
   > Total Current Liabilities 
0
0
0
65,324
68,830
86,752
83,111
71,906
71,033
95,659
102,511
103,319
101,171
101,591
102,526
89,367
92,371
99,611
96,116
87,355
92,117
83,483
82,954
74,058
83,715
91,905
88,585
82,626
84,543
85,244
84,748
70,623
79,400
84,955
77,911
87,164
87,023
91,496
84,697
83,110
85,428
94,577
78,483
72,382
68,641
70,810
60,769
60,439
103,758
108,447
105,723
94,919
83,793
77,334
81,444
86,346
80,648
96,087
89,940
97,320
89,029
85,509
86,625
95,888
92,270
92,27095,88886,62585,50989,02997,32089,94096,08780,64886,34681,44477,33483,79394,919105,723108,447103,75860,43960,76970,81068,64172,38278,48394,57785,42883,11084,69791,49687,02387,16477,91184,95579,40070,62384,74885,24484,54382,62688,58591,90583,71574,05882,95483,48392,11787,35596,11699,61192,37189,367102,526101,591101,171103,319102,51195,65971,03371,90683,11186,75268,83065,324000
       Short-term Debt 
0
0
0
0
0
35,404
0
0
34,987
45,428
57,181
62,860
57,807
54,453
0
52,686
54,847
53,020
54,458
54,734
56,511
46,556
48,923
41,327
48,874
52,230
50,289
44,466
46,048
40,401
41,741
28,629
35,671
34,655
28,541
27,906
28,737
29,825
27,253
26,395
30,655
42,620
33,140
28,483
34,666
32,522
30,487
31,333
18,562
20,016
18,624
16,783
17,986
17,950
16,159
14,031
14,337
12,742
15,133
14,733
14,854
14,619
14,753
14,504
12,794
12,79414,50414,75314,61914,85414,73315,13312,74214,33714,03116,15917,95017,98616,78318,62420,01618,56231,33330,48732,52234,66628,48333,14042,62030,65526,39527,25329,82528,73727,90628,54134,65535,67128,62941,74140,40146,04844,46650,28952,23048,87441,32748,92346,55656,51154,73454,45853,02054,84752,686054,45357,80762,86057,18145,42834,9870035,40400000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95,489
94,659
103,734
13,687
14,065
14,507
14,684
16,335
13,508
32,852
30,773
28,722
29,655
17,004
18,524
17,051
15,313
16,235
16,152
14,368
12,212
12,183
10,736
13,776
13,125
13,213
12,748
12,777
12,825
10,920
10,92012,82512,77712,74813,21313,12513,77610,73612,18312,21214,36816,15216,23515,31317,05118,52417,00429,65528,72230,77332,85213,50816,33514,68414,50714,06513,687103,73494,65995,48900000000000000000000000000000000000
       Accounts payable 
0
0
0
29,491
0
37,538
0
30,183
0
0
0
32,677
0
0
0
29,879
0
0
0
23,782
29,742
30,074
25,247
22,364
27,655
31,015
28,485
26,070
30,479
36,298
32,546
30,880
36,400
41,397
39,021
36,712
40,885
42,617
36,470
35,830
37,778
41,097
35,731
31,231
23,756
25,182
19,198
16,471
15,002
15,170
15,987
21,039
20,696
15,752
19,160
26,928
26,353
24,689
31,117
27,492
21,075
23,134
21,284
31,308
34,631
34,63131,30821,28423,13421,07527,49231,11724,68926,35326,92819,16015,75220,69621,03915,98715,17015,00216,47119,19825,18223,75631,23135,73141,09737,77835,83036,47042,61740,88536,71239,02141,39736,40030,88032,54636,29830,47926,07028,48531,01527,65522,36425,24730,07429,74223,78200029,87900032,67700030,183037,538029,491000
       Other Current Liabilities 
0
0
0
35,833
68,830
8,188
83,111
41,723
36,046
50,231
45,330
7,782
43,364
47,138
102,526
2,125
37,524
46,591
41,658
106
2,046
2,672
2,838
1,008
3,178
4,241
3,349
1,001
3,758
3,418
3,044
1,441
3,236
3,889
3,059
1,713
5,190
4,191
3,232
2,826
4,773
4,674
2,476
2,954
-20,779
3,724
2,407
2,575
85,196
6,598
3,083
4,902
8,187
7,508
7,501
5,833
39,958
30,678
43,690
30,429
28,531
16,105
17,351
25,130
19,571
19,57125,13017,35116,10528,53130,42943,69030,67839,9585,8337,5017,5088,1874,9023,0836,59885,1962,5752,4073,724-20,7792,9542,4764,6744,7732,8263,2324,1915,1901,7133,0593,8893,2361,4413,0443,4183,7581,0013,3494,2413,1781,0082,8382,6722,04610641,65846,59137,5242,125102,52647,13843,3647,78245,33050,23136,04641,72383,1118,18868,83035,833000
   > Long-term Liabilities 
0
0
0
92,872
91,907
95,303
98,976
98,272
104,474
107,972
99,114
92,644
88,653
96,681
95,718
93,947
90,968
85,892
81,416
73,749
69,828
71,006
66,259
65,877
55,635
63,043
59,196
58,694
55,098
65,337
84,031
68,280
73,121
76,932
75,503
85,478
83,522
87,507
82,783
81,626
78,575
69,907
68,127
67,821
89,965
62,708
60,977
56,810
94,471
140,282
125,858
132,618
133,784
130,354
123,043
104,122
95,579
87,749
76,654
72,982
67,757
62,879
56,592
51,897
48,954
48,95451,89756,59262,87967,75772,98276,65487,74995,579104,122123,043130,354133,784132,618125,858140,28294,47156,81060,97762,70889,96567,82168,12769,90778,57581,62682,78387,50783,52285,47875,50376,93273,12168,28084,03165,33755,09858,69459,19663,04355,63565,87766,25971,00669,82873,74981,41685,89290,96893,94795,71896,68188,65392,64499,114107,972104,47498,27298,97695,30391,90792,872000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,897
28,534
29,059
0
0
0
00029,05928,53427,89700000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,895
17,600
13,600
11,105
8,019
7,910
2,665
2,567
2,899
26,056
2,091
2,137
2,028
49,399
97,457
84,209
92,736
97,382
91,073
84,698
68,820
62,219
55,871
49,369
45,085
0
0
0
0
0
0000045,08549,36955,87162,21968,82084,69891,07397,38292,73684,20997,45749,3992,0282,1372,09126,0562,8992,5672,6657,9108,01911,10513,60017,60017,89500000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,543
0
0
0
10,976
0
0
0
5,482
0
0
0
5,151
0
0
0
2,807
0
0
0
2,105
0
0
0
1,403
0
0
0
0
0
000001,4030002,1050002,8070005,1510005,48200010,97600013,54300000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
49,344
45,415
48,996
46,452
41,136
40,479
39,094
36,925
34,515
33,023
33,052
27,973
39,553
35,399
48,170
44,820
42,330
58,195
56,609
56,385
53,228
69,674
68,932
69,598
63,882
69,945
76,352
80,742
76,874
69,313
62,492
59,968
52,358
49,964
47,064
39,107
26,866
25,532
30,024
32,135
21,373
11,401
129
-5,296
11,374
81,304
107,434
98,150
102,722
127,525
134,854
143,205
177,918
201,801
206,936
212,504
222,957
216,931
210,302
206,195
193,438
192,674
192,674193,438206,195210,302216,931222,957212,504206,936201,801177,918143,205134,854127,525102,72298,150107,43481,30411,374-5,29612911,40121,37332,13530,02425,53226,86639,10747,06449,96452,35859,96862,49269,31376,87480,74276,35269,94563,88269,59868,93269,67453,22856,38556,60958,19542,33044,82048,17035,39939,55327,97333,05233,02334,51536,92539,09440,47941,13646,45248,99645,41549,344000
   Common Stock
0
0
0
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,110
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,132
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,013
11,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,01311,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,13211,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,11011,110000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19
0
0
0
15
0
0150001900000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
71,278
71,278
71,278
0
0
0
00071,27871,27871,27800000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
296,078
296,096
63,167
306,369
311,298
312,809
312,822
313,388
-266,045
314,934
314,907
314,907
316,415
317,777
317,468
316,732
316,953
317,015
317,474
317,474
317,260
316,834
316,148
315,967
314,542
313,739
323,292
323,292
66,253
65,830
65,028
66,032
65,953
66,141
67,888
66,807
66,821
66,744
67,877
68,759
69,047
69,658
69,057
69,187
69,794
67,851
59,880
36,905
49,839
48,971
48,949
46,978
45,618
49,309
53,273
50,905
55,413
48,587
51,109
46,212
40,187
37,570
37,57040,18746,21251,10948,58755,41350,90553,27349,30945,61846,97848,94948,97149,83936,90559,88067,85169,79469,18769,05769,65869,04768,75967,87766,74466,82166,80767,88866,14165,95366,03265,02865,83066,253323,292323,292313,739314,542315,967316,148316,834317,260317,474317,474317,015316,953316,732317,468317,777316,415314,907314,907314,934-266,045313,388312,822312,809311,298306,36963,167296,096296,078000



Balance Sheet

Currency in EUR. All numbers in thousands.